Enlivex Therapeutics (ENLV) has released an update.
Enlivex Therapeutics, a clinical-stage immunotherapy company, has reported promising results from Phase II trials of their drug Allocetra, which has demonstrated potential in treating life-threatening conditions like sepsis and has shown remarkable recovery in critical COVID-19 cases. The company is also exploring Allocetra’s use in treating osteoarthritis, with ongoing trials and significant milestones expected in the near future. Enlivex’s CEO, Oren Hershkovitz, expresses optimism about Allocetra’s ability to become a transformative treatment in medicine, backed by sufficient cash resources for upcoming clinical trials.
For further insights into ENLV stock, check out TipRanks’ Stock Analysis page.
